Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02723955
Additional trial details provided through ANZCTR are available at the end of this record.
Registration number
NCT02723955
Ethics application status
Date submitted
24/03/2016
Date registered
31/03/2016
Date last updated
21/02/2024
Titles & IDs
Public title
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Query!
Scientific title
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
2016-000148-32
Query!
Secondary ID [2]
0
0
204691
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neoplasms
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - feladilimab (GSK3359609)
Treatment: Drugs - GSK3174998
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Docetaxel
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Paclitaxel plus Carboplatin
Treatment: Drugs - Gemcitabine plus Carboplatin
Treatment: Drugs - Fluorouracil (5-FU) plus carboplatin or cisplatin
Treatment: Drugs - Dostarlimab
Treatment: Drugs - Cobolimab
Treatment: Drugs - Bintrafusp alfa
Experimental: Part 1A: Dose escalation feladilimab (GSK3359609) - Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
Experimental: Part 1B: Expansion feladilimab (GSK3359609) - Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
Experimental: Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab) - Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
Experimental: Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998) - Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
Experimental: Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy) - Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
Experimental: Part 2B: Expansion-feladilimab (GSK3359609) - Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
Experimental: Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab) - Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
Experimental: Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab) - Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
Experimental: Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa) - Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
Treatment: Drugs: feladilimab (GSK3359609)
Treatment: Drugs: GSK3174998
Treatment: Drugs: Pembrolizumab
Treatment: Drugs: Docetaxel
Treatment: Drugs: Pemetrexed
Treatment: Drugs: Paclitaxel plus Carboplatin
Treatment: Drugs: Gemcitabine plus Carboplatin
Treatment: Drugs: Fluorouracil (5-FU) plus carboplatin or cisplatin
Treatment: Drugs: Dostarlimab
Treatment: Drugs: Cobolimab
Treatment: Drugs: Bintrafusp alfa
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Parts 1 and 2: Number of participants with any months adverse event(s) (AE) and serious adverse event(s) (SAE)
Query!
Assessment method [1]
0
0
AEs and SAEs will be collected.
Query!
Timepoint [1]
0
0
Up to 27 months
Query!
Primary outcome [2]
0
0
Parts 1 and 2: Number of participants with dose limiting toxicity (DLT)
Query!
Assessment method [2]
0
0
Number of participants with DLTs will be assessed.
Query!
Timepoint [2]
0
0
Up to 28 days
Query!
Primary outcome [3]
0
0
Parts 1 and 2: Number of participants with clinically significant changes in laboratory parameters and vital signs
Query!
Assessment method [3]
0
0
Number of participants with clinically significant changes in laboratory parameters and vital signs will be assessed.
Query!
Timepoint [3]
0
0
Up to 24 months
Query!
Primary outcome [4]
0
0
Parts 1 and 2: Number of participants requiring dose modifications
Query!
Assessment method [4]
0
0
All dose modifications due to any reason(s) will be recorded.
Query!
Timepoint [4]
0
0
Up to 24 months
Query!
Secondary outcome [1]
0
0
Parts 1 and 2: Disease control rate (DCR)
Query!
Assessment method [1]
0
0
DCR is defined as the percentage of participants with a confirmed complete response (CR) + partial response (PR) at any time, plus stable disease (SD) >=18 weeks.
Query!
Timepoint [1]
0
0
Up to 27 months
Query!
Secondary outcome [2]
0
0
Parts 1 and 2: Overall survival (OS)
Query!
Assessment method [2]
0
0
OS is defined as time from the date of first dose of study treatment to the date of death due to any cause.
Query!
Timepoint [2]
0
0
Up to 4 years
Query!
Secondary outcome [3]
0
0
Parts 1 and 2: Progression-free survival (PFS)
Query!
Assessment method [3]
0
0
PFS is defined as time from the date of first dose of study treatment to the date of disease progression according to clinical or radiographic assessment or death due to any cause, whichever occurs earliest.
Query!
Timepoint [3]
0
0
Up to 27 months
Query!
Secondary outcome [4]
0
0
Parts 1 and 2: Time to overall response (TTR)
Query!
Assessment method [4]
0
0
TTR will be summarized for participants with a confirmed CR or PR and is defined as the time from date of first dose of study treatment to date of first documented confirmed CR or PR.
Query!
Timepoint [4]
0
0
Up to 27 months
Query!
Secondary outcome [5]
0
0
Parts 1 and 2: Duration of response (DOR)
Query!
Assessment method [5]
0
0
DOR will be summarized for participants with a confirmed CR or PR and is defined as the time from date of initial confirmed response to the date of disease progression or death due to any cause.
Query!
Timepoint [5]
0
0
Up to 27 months
Query!
Secondary outcome [6]
0
0
Parts 1 and 2: Overall response rate (ORR)
Query!
Assessment method [6]
0
0
ORR is defined as the percentage of participants with a best overall confirmed CR or a PR at any time as per disease-specific criteria.
Query!
Timepoint [6]
0
0
Up to 27 months
Query!
Secondary outcome [7]
0
0
Parts 1 and 2: Maximum observed plasma concentration (Cmax) and minimum observed plasma concentration (Cmin) of GSK3359609
Query!
Assessment method [7]
0
0
Blood samples will be collected for the concentrations of GSK3359609.
Query!
Timepoint [7]
0
0
Up to 27 months
Query!
Secondary outcome [8]
0
0
Parts 1 and 2: Area under the concentration-time curve over the dosing interval (AUC[0-tau]) of GSK3359609 in plasma
Query!
Assessment method [8]
0
0
Blood samples will be collected for the concentrations of GSK3359609.
Query!
Timepoint [8]
0
0
Up to 27 months
Query!
Secondary outcome [9]
0
0
Parts 1 and 2: Number of participants with positive results in Anti-drug antibody (ADA) test by GSK3359609 dose level
Query!
Assessment method [9]
0
0
Blood samples will be collected up to 27 months for ADA test.
Query!
Timepoint [9]
0
0
Up to 27 months
Query!
Secondary outcome [10]
0
0
Part 1 and 2: Number of participants with positive results in GSK3359609
Query!
Assessment method [10]
0
0
Blood samples will be collected up to 27 months for immunogenicity.
Query!
Timepoint [10]
0
0
Up to 27 months
Query!
Secondary outcome [11]
0
0
Part 2: Number of participants with DLT following administration of GSK3359609 in combination with chemotherapies
Query!
Assessment method [11]
0
0
Number of participants with DLTs will be assessed.
Query!
Timepoint [11]
0
0
Up to 28 days
Query!
Secondary outcome [12]
0
0
Part 2: Cmax and Cmin of GSK3174998
Query!
Assessment method [12]
0
0
Blood samples will be collected for the concentrations of GSK3174998.
Query!
Timepoint [12]
0
0
Up to 24 months
Query!
Secondary outcome [13]
0
0
Part 2: AUC(0-tau) of GSK3174998
Query!
Assessment method [13]
0
0
Blood samples will be collected for the concentrations of GSK3174998.
Query!
Timepoint [13]
0
0
Up to 24months
Query!
Secondary outcome [14]
0
0
Part 2: Cmax and Cmin of Pembrolizumab
Query!
Assessment method [14]
0
0
Blood samples will be collected for the concentrations of Pembrolizumab.
Query!
Timepoint [14]
0
0
Up to 27 months
Query!
Secondary outcome [15]
0
0
Part 2: AUC(0-tau) of Pembrolizumab
Query!
Assessment method [15]
0
0
Blood samples will be collected for the concentrations of Pembrolizumab.
Query!
Timepoint [15]
0
0
Up to 27 months
Query!
Secondary outcome [16]
0
0
Part 2: Number of participants with positive results in ADA test by GSK3359609 in combination with pembrolizumab or GSK3174998 dose level
Query!
Assessment method [16]
0
0
Blood samples will be collected up to 27 months for ADA test.
Query!
Timepoint [16]
0
0
Up to 27 months
Query!
Secondary outcome [17]
0
0
Part 2: Number of participants with positive results in Pembrolizumab
Query!
Assessment method [17]
0
0
Blood samples will be collected up to 27 months for immunogenicity.
Query!
Timepoint [17]
0
0
Up to 27 months
Query!
Secondary outcome [18]
0
0
Part 2: Number of participants with positive results in GSK3174998
Query!
Assessment method [18]
0
0
Blood samples will be collected up to 27 months for immunogenicity.
Query!
Timepoint [18]
0
0
Up to 27 months
Query!
Secondary outcome [19]
0
0
Part 2: Cmax and Cmin of GSK3359609 combination with chemotherapies
Query!
Assessment method [19]
0
0
Blood samples will be collected for the concentrations of GSK3359606 in combination with chemotherapies.
Query!
Timepoint [19]
0
0
Up to 27 months
Query!
Secondary outcome [20]
0
0
Part 2: Number of participants with positive results in ADA test by GSK3359609 combination with chemotherapies dose level
Query!
Assessment method [20]
0
0
Blood samples will be collected up to 27 months for ADA test.
Query!
Timepoint [20]
0
0
Up to 27 months
Query!
Secondary outcome [21]
0
0
Part 2: Cmax and Cmin of dostarlimab
Query!
Assessment method [21]
0
0
Blood samples will be collected for the concentrations of dostarlimab.
Query!
Timepoint [21]
0
0
Up to 27 months
Query!
Secondary outcome [22]
0
0
Part 2: AUC(0-tau) of dostarlimab
Query!
Assessment method [22]
0
0
Blood samples will be collected for the concentrations of dostarlimab.
Query!
Timepoint [22]
0
0
Up to 27 months
Query!
Secondary outcome [23]
0
0
Part 2: Cmax and Cmin of cobolimab
Query!
Assessment method [23]
0
0
Blood samples will be collected for the concentrations of cobolimab.
Query!
Timepoint [23]
0
0
Up to 27 months
Query!
Secondary outcome [24]
0
0
Part 2: AUC(0-tau) of cobolimab
Query!
Assessment method [24]
0
0
Blood samples will be collected for the concentrations of cobolimab.
Query!
Timepoint [24]
0
0
Up to 27 months
Query!
Secondary outcome [25]
0
0
Part 2: Cmax and Cmin of bintrafusp alfa
Query!
Assessment method [25]
0
0
Blood samples will be collected for the concentrations of bintrafusp alfa.
Query!
Timepoint [25]
0
0
Up to 27 months
Query!
Secondary outcome [26]
0
0
Part 2: AUC(0-tau) of bintrafusp alfa
Query!
Assessment method [26]
0
0
Blood samples will be collected for the concentrations of bintrafusp alfa.
Query!
Timepoint [26]
0
0
Up to 27 months
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Capable of giving signed, written informed consent.
- Male or female, age >=18 years (at the time consent is obtained).
- Histological or cytological documentation of an invasive malignancy that was diagnosed
as locally advanced/metastatic or relapsed/refractory and is of one of the following
tumor types: bladder/urothelial cancer of the upper and lower urinary tract; cervical;
colorectal (includes appendix); esophagus, squamous cell; head and neck carcinoma;
melanoma; malignant pleural mesothelioma (MPM); non-small-cell lung cancer (NSCLC),
prostate; Microsatellite Instability-High/deficient mismatch repair (MSI-H/dMMR) tumor
(Part 1B and Part 2B) and Human Papilloma Virus (HPV)-positive or Epstein-Barr
(EBV)-positive tumor (Part 1B and Part 2B).
- Disease that has progressed after standard therapy for the specific tumor type, or for
which standard therapy has proven to be ineffective, intolerable, or is considered
inappropriate, or if no further standard therapy exists; exceptions are in these tumor
types in which pembrolizumab single agent may be a standard: NSCLC, head and neck
squamous cell cancer (HNSCC), bladder/urothelial cancer, MSI-H/dMMR cancers and
melanoma and cervical cancer. In Part 2B pembrolizumab combination expansion cohorts,
prior treatment with anti-Programmed cell death protein 1(PD-1)/ Ligand-1 (L1) may not
be required. 1) Participants must not have received more than 5 prior lines of therapy
for advanced disease including both standards of care and investigational therapies.
2) Participants who received prior PD-1/L1 therapy must fulfill the following
requirements (Part 1B [except PK/PD cohort]/ Part 2B):a) Have achieved a CR, PR or SD
and subsequently had disease progression while still on PD-1/L1 therapy; b) Have
received at least 2 doses of an approved PD-1/L1 inhibitor (by any regulatory
authority), c) Have demonstrated disease progression as defined by Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 within 18 weeks from the last dose of
the PD-1/L1 inhibitor. The initial evidence of disease progression is to be confirmed
by a second assessment no less than four weeks from the date of the first documented
Progressive Disease (PD) (the confirmatory scan could be the Baseline eligibility scan
for this study). 3) In Part 2A 5-fluorouracil (FU)/platinum combination with
GSK3359609 and pembrolizumab cohort, participants must not have received prior
systemic therapy administered in the recurrent or metastatic setting (with the
exception of systemic therapy given as part of multimodal treatment for locally
advanced disease).
- Archival tumor tissue obtained at any time from the initial diagnosis to study entry;
a fresh tumor biopsy using a procedure that is safe for the participant on a lesion
not previously irradiated unless lesion progressed will be required if archival tissue
is unavailable.
- Agree to undergo a pre-treatment and on treatment biopsy and have disease amenable to
biopsy required in pharmacokinetic (PK) / pharmacodynamics (PD), dose randomized
HNSCC, Melanoma dose expansion and Biomarker cohorts..
- Measurable disease per RECIST version 1.1. Palpable lesions that are not measurable by
radiographic or photographic evaluations may not be utilized as the only measurable
lesion. Any measurable lesion biopsied at Screening cannot be followed as a
target/index lesion unless agreed upon by GlaxoSmithKline (GSK).
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
- Life expectancy of at least 12 weeks.
- Adequate organ function.
- QT interval corrected for heart rate according to Fridericia's formula (QTcF) <450
milliseconds (msec) or QTcF <480 msec for participants with bundle branch block.
- A female participant is eligible to participate if she is not pregnant (as confirmed
by a negative serum beta-human chorionic gonadotrophin [beta-hCG] test in females of
reproductive potential), and not lactating or reproductive potential agrees to follow
one of the options listed in protocol from 30 days prior to the first dose of study
medication and until 120 days after the last dose of study treatment.
- Male participants with female partners of child bearing potential must agree to use
one of the methods of contraception specified in protocol from time of first dose of
study treatment until 120 days after the last dose of study treatment.
- Documented HPV/ EBV-positive tumor as determined by a local laboratory for Part 1B and
Part 2B pembrolizumab combination viral-positive expansion cohorts only.
- Documented MSI-H or dMMR-positive tumor as determined by local laboratory for Part 1B
and Part 2B pembrolizumab combination MSI-H/dMMR expansion cohorts only.
- ICOS expression result using an analytically validated immunohistochemistry (IHC)
assay by central laboratory for Part 1B biomarker cohort only.
- Gene expression (GEX) result using an analytically validated method by central
laboratory (Part 1B Biomarker Cohort only).
- PD-L1 combined positive score (CPS) <1 using the Food and Drug Administration (FDA)
approved PD-L1 IHC 22C3 pharmdx assay by central laboratory testing for Part 2B HNSCC
PD-L1 CPS <1 Cohort. Documented test result from FDA approved PD-L1 IHC 22C3 pharmDx
assay in local laboratory, if available, may be accepted in lieu of the central
laboratory test result.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Prior treatment with the following therapies:
- Anticancer therapy within 30 days or 5 half-lives of the drug, whichever is
shorter. At least 14 days must have elapsed between the last dose of prior
anticancer agent and the first dose of study drug is administered.
- Part 2B (GSK3359609/pembrolizumab combination): prior pembrolizumab washout is
not required.
- Prior radiation therapy: permissible if at least one non-irradiated measurable
lesion is available for assessment according to RECIST version 1.1 or if a
solitary measurable lesion was irradiated, objective progression is documented. A
wash out of at least two weeks before start of study drug for radiation of any
intended use to the extremities for bone metastases and 4 weeks for radiation to
the chest, brain, or visceral organs is required. • Investigational therapy
within 30 days or 5 half-lives of the investigational product (whichever is
shorter). At least 14 days must have elapsed between the last dose of
investigational agent and the first dose of study drug is administered.
- Prior allogeneic or autologous bone marrow transplantation or other solid organ
transplantation.
- Toxicity from previous anticancer treatment
- Invasive malignancy or history of invasive malignancy other than disease under study
within the last two years except: Any other invasive malignancy for which the
participant was definitively treated, has been disease-free for <=2 years and in the
opinion of the principal investigator and GSK Medical Monitor will not affect the
evaluation of the effects of the study treatment on the currently targeted malignancy,
may be included in this clinical trial; and curatively treated non-melanoma skin
cancer.
- Central nervous system (CNS) metastases, with the following exception: • Participants
who have previously-treated CNS metastases, are asymptomatic, and have no requirement
for steroids at least 14 days prior to first dose of study drug. Participants with
carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical
stability.
- Received transfusion of blood products (including platelets or red blood cells) or
administration of colony stimulating factors (including granulocyte colony-stimulating
factor [G-CSF], granulocyte-macrophage colony-stimulating factor, recombinant
erythropoietin) within 14 days prior to the first dose of GSK3359609.
- Major surgery <=4 weeks before the first dose of study treatment. Participants must
have also fully recovered from any surgery (major or minor) and/or its complications
before initiating study treatment.
- Active autoimmune disease that has required systemic treatment within the last two
years (i.e., with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine or physiologic
corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is
not considered a form of systemic treatment.
- Concurrent medical condition requiring the use of systemic immunosuppressive
medications within 7 days before the first dose of study treatment. Physiologic doses
of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic
absorption, including topical, inhaled, or intranasal corticosteroids may be continued
if the participant is on a stable dose.
- Condition requiring treatment with strong inhibitors/inducers of cytochrome p (CYP)
450 3A4 within 7 days prior to first dose of chemotherapy (requirement applies to
participants enrolled to Part 2 chemotherapy combination with docetaxel).
- Active infection requiring systemic therapy, known human immunodeficiency virus
infection, or positive test for hepatitis B active infection or hepatitis C active
infection.
- Current active liver or biliary disease (with the exception of Gilbert's syndrome or
asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease
per investigator assessment).
- Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel
disease, intra-abdominal abscess, or gastrointestinal obstruction that required
surgery.
- Receipt of any live vaccine within 4 weeks prior to first dose of study treatment.
- Recent history of allergen desensitization therapy within 4 weeks of starting study
treatment.
- History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies
under investigation including any ingredient used in the formulation.
- History or evidence of cardiac abnormalities.
- History of (current and past) idiopathic pulmonary fibrosis, pneumonitis (for past
pneumonitis exclusion only if steroids were required for treatment), interstitial lung
disease, or organizing pneumonia. Note: post-radiation changes in the lung related to
prior radiotherapy and/or asymptomatic radiation-induced pneumonitis not requiring
treatment may be permitted if agreed by the investigator and Medical Monitor.
- Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural
effusions.
- Any serious and/or unstable pre-existing medical, psychiatric disorder, or other
condition that could interfere with the participant's safety, obtaining informed
consent, or compliance to the study procedures.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/06/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
5/07/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
829
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [2]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Oklahoma
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Pennsylvania
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Tennessee
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Ontario
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Shnghai
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Bordeaux Cedex
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Lyon cedex 08
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Paris
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Villejuif cedex
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Toscana
Query!
Country [14]
0
0
Japan
Query!
State/province [14]
0
0
Chiba
Query!
Country [15]
0
0
Japan
Query!
State/province [15]
0
0
Osaka
Query!
Country [16]
0
0
Japan
Query!
State/province [16]
0
0
Tokyo
Query!
Country [17]
0
0
Netherlands
Query!
State/province [17]
0
0
Amsterdam
Query!
Country [18]
0
0
Spain
Query!
State/province [18]
0
0
Barcelona
Query!
Country [19]
0
0
Spain
Query!
State/province [19]
0
0
Madrid
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Málaga
Query!
Country [21]
0
0
Spain
Query!
State/province [21]
0
0
Sevilla
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Merck Sharp & Dohme LLC
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody
intended for the treatment of cancers of different histology. This is a first-time-in-human
(FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and
preliminary antitumor activity in participants with selected, advanced or recurrent solid
tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as
monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is
comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy
with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2:
GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or dostarlimab or
dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B
expansion phase with pembrolizumab. Part 2A GSK3359609 combinations with chemotherapy will
only consist of safety run-in cohorts. Each part and phase of the study includes a screening
period, a treatment period, and a follow-up period. The primary objective of the study is to
determine the safety, tolerability, maximum tolerated dose or the maximum administered dose
of GSK3359609 alone or in combination.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02723955
Query!
Trial related presentations / publications
Turner DC, Wada R, Zhou H, Wang X, de Greef R, Valiathan C, Zhang L, Zhang N, Kuchimanchi M, Chen TT, Ballas M, Visser SAG. Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1751-1763. doi: 10.1002/psp4.12917. Epub 2023 Jan 31.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02723955
Additional trial details provided through ANZCTR
Accrual to date
Recruiting in Australia
Recruitment state(s)
WA,VIC
Funding & Sponsors
Primary sponsor
Commercial sector/Industry
Primary sponsor name
GlaxoSmithKline
Primary sponsor address
Primary sponsor country
Ethics approval
Ethics application status
Approved
Public notes
Investigators:
Michael Millward, Sir Charles Gairdner Hospital, Western Australia, Nedlands, Australia, 6009
Hui Gan, Austin Health, Victoria, Heidelberg, Australia, 3084
Danny Rischin, Peter MacCallum Cancer Institute, Victoria, Melbourne, Australia, 3000
Contacts
Principal investigator
Title
73
0
Query!
Name
73
0
Query!
Address
73
0
Query!
Country
73
0
Query!
Phone
73
0
Query!
Fax
73
0
Query!
Email
73
0
Query!
Contact person for public queries
Title
74
0
Query!
Name
74
0
Query!
Address
74
0
Query!
Country
74
0
Query!
Phone
74
0
Query!
Fax
74
0
Query!
Email
74
0
[email protected]
Query!
Contact person for scientific queries
Title
75
0
Query!
Name
75
0
Query!
Address
75
0
Query!
Country
75
0
Query!
Phone
75
0
Query!
Fax
75
0
Query!
Email
75
0
[email protected]
Query!
Download to PDF